Morozov Dmitry Valentinovich

Morozov Dmitry Valentinovich

Biography

2020: Opening of the Yuninov Medical Center in St. Petersburg

On October 7, 2020, the opening of the Yuninov Research Medical Center in St. Petersburg took place. Its sole founder was Dmitry Morozov, general director and co-owner of the pharmaceutical company Biocad. Read more here.

2022: Biocad Board Chairman

Dmitry Morozov moved to the position of Chairman of the Board of Directors of BIOCAD. The company announced this on March 4, 2022.

In this position, he focused on strategic issues of the company's development. Dmitry Morozov will continue to oversee a number of areas personally.

Dmitry Sivokoz, Vice President for Marketing, Sales and Market Access, has been appointed General Director of the company.

Awards and titles

2019: Award of the Medal of the Order "For Merit to the Fatherland" II degree

On September 10, 2019, information appeared that by decree of the President of the Russian Federation, the medal of the Order of Merit for the Fatherland, II degree, was awarded to Dmitry Morozov, General Director and co-owner of Biocad CJSC. The award was awarded to the head of the Russian biotechnology company in accordance with Decree No. 392 "On Awarding State Awards of the Russian Federation" dated 23.08.2019.

Awarding Dmitry Morozov with a medal of the Order "For Merit to the Fatherland" II degree

In 2010, under the leadership of Dmitry Morozov, the company launched a project to create drugs based on monoclonal antibodies: biosimilars rituximab, trastuzumab and bevacizumab for the treatment of cancer. Previously, vital drugs were presented only by imported manufacturers. On April 4, 2014, the Ministry of Health of the Russian Federation registered the first biosimilar of the domestically produced drug rituximab in Russia.

Morozov used the research experience acquired by the company during the implementation of the project to organize the development of advanced original drugs based on monoclonal antibodies for the treatment of cancer and autoimmune diseases. The first original drug based on monoclonal antibodies for psoriasis therapy is already on sale, the second - an immune therapy drug for the treatment of patients with melanoma - at the final stage of clinical trials.

Pharmbusiness is tough, not for the faint of heart, it is built on those difficult situations in which people fall. To achieve something in this extremely difficult and closed sphere, you need to immerse yourself in it very deeply, - the entrepreneur recalled years later. - In Russia, biotechnological companies that have done something can be counted on one hand, although there were once quite a few of them created, mainly by immigrants from the academic environment. The success and rapid growth of Biocad became possible, primarily due to the team, the readiness of each employee to work daily and grow over himself. In fact, the reward in my face is received not by me, but by the team.

As noted, investments in education and training of scientific personnel are still one of the strategic steps of Dmitry Morozov as the head of a biotechnology company. Partnerships and cooperation with leading schools and universities are the main vectors of the company's social policy, aimed primarily at training personnel for the company and the industry as a whole.

Dmitry Morozov is also a co-author of the federal target program for the development of the pharmaceutical industry of Russia "Pharma - 2020." The program was approved by Decree of the Government of the Russian Federation of 17.02.2011 No. 91.

2020: Laureate of the State Prize of Russia in the field of science and technology

The award "for the development and introduction into clinical practice of a complex of drugs based on monoclonal antibodies for the treatment of cancer and autoimmune diseases" was received by the general director of Biocad Dmitry Morozov, Candidate of Biological Sciences, Director of the Biochemistry Department of BIOCAD Tatyana Chernovskaya and Acting Researcher of the Institute of Biological Instrumentation with Experimental Production of the Russian Academy of Sciences of the Pushchinsky Scientific Center for Biological Research of the Russian Academy of Sciences Andrei Ulitin. Biocad announced this on June 18, 2020.

{{quote 'The award award is another marker for me and my colleagues that, that twenty years ago we took the right direction and chose the right goal - to fight cancer, - commented on the news of the award Dmitry Morozov, CEO of BIOCAD. - This is not just a fight against the disease, we are talking about extending the specific lives of people and increasing the life expectancy of the entire nation, all citizens of Russia. Humanity has already learned to cope with many diseases, cancer is one of the barriers to a long life, during which each person can achieve many goals, learn something new, create, love and take care of loved ones. We are grateful for this award, which will be an incentive for our entire team to go further, look for and win other peaks. }}

The analysis of government purchases of monoclonal antibodies bevacizumab, trastuzumab and rituximab in the period from 2013 to 2019 showed that the production of these biosimilars in Russia allowed to reduce purchase prices for drugs by 30-85%. Reducing the cost of drug therapy made it possible to increase the number of patients who received the necessary treatment several times.

Achievements in the development of scientific and practical platform solutions were also highly appreciated, including the automated MabNext platform, which provides the ability to obtain antibodies to almost any target that is a membrane or secreted protein. Thanks to this platform, the transition to preclinical tests is carried out for 3-5 projects per year.

2022: Award of the "Order of Friendship"

The Chairman of the Board of Directors of BIOCAD was awarded the Order of Friendship for the high-quality and uninterrupted production of Russian vaccines against coronavirus. This became known on June 3, 2022.

The awards were presented by President RFVladimir Putin.

Dmitry Morozov, Chairman of the Board of Directors of Biocad JSC, was awarded the Order of Friendship.

The medal of the Order of Merit for the Fatherland, II degree, was received by Deputy General Director for Production and Technical Support of the company Alexander Grachev, as well as Director of the Production Department Yegor Bystrov.

The top management of BIOCAD has repeatedly emphasized that the process of prompt release of the vaccine required a lot of effort from the company, including because the task was to maintain the planned production of drugs for the treatment of cancer and autoimmune diseases - the main profile of activity.